Skip to main content Accessibility help
×
Home

Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia: Submitted to European Psychiatry. A poster of this work was presented at the WPA International Congress in Florence (November 10–13, 2004). Poster session PO1: Psychotic Disorders

  • José Luis R. Martin (a1) (a2), Víctor Pérez (a3), Montse Sacristán (a1), Fernando Rodríguez-Artalejo (a4), Cristóbal Martínez (a5) and Enric Álvarez (a3)...

Abstract

Objective

To assess antipsychotic medication in the treatment of schizophrenia, based on trial drop-out rates.

Methods

The studies included were randomised controlled trials that compared any of the four clinically best-established atypical antipsychotics (quetiapine, olanzapine, risperidone or clozapine) against either of two typical antipsychotics regarded as the gold standard (haloperidol or chlorpromazine).

Results

Meta-analysis indicated less risk of all-cause patient withdrawal from atypical medication trials where dosage was flexible, in both the short, relative risk (RR) 0.70 (95% CI 0.64–0.76), P < 0.00001, and long term, RR 0.72 (0.65–0.80), P < 0.00001. Similar results were observed for withdrawal due to adverse events, RR: 0.54 (0.41–0.72), P < 0.0001. Nevertheless, the favourable effects of atypical medication disappeared in trials relying on fixed dosage.

Conclusions

We detected a significant positive effect in terms of the outcome of treatment discontinuation for atypical versus typical medication, though only where the use of flexible rather than fixed doses (closer to an experimental control situation) was possible.

Copyright

Corresponding author

*Corresponding author. Tel.: +34 92 528 1144; fax: +34 92 528 1149. E-mail address:jlrmartin@jccm.es (J.L.R. Martin).

References

Hide All
[1]Daumit, GLCrum, RMGuallar, EPowe, NRPrimm, ABSteinwachs, DMet al.Outpatients prescriptions for atypical antipsychotics for African Americans, Hispanics, and Whites in the United States. Arch. Gen. Psychiatry 2003;60:121128.
[2]Lieberman, JAAtypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J. Clin. Psychiat. 1996;57(11):6871.
[3]Sarif, ZACommon treatment goals of antipsychotics: acute treatment. J. Clin. Psychiat. 1998;59(19):58.
[4]Kay, SRFiszbein, AThe positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261275.
[5]Chouinard, GJones, BRemington, GBlooom, DAddington, DMacEwan, GWet al.A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharm. 1993;13:2540.
[6]Hamilton, SHRevicki, DAGenduso, LABeasley, CMOlanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American Double-blind trial. Neuropsychopharmacol 1998;18:4149.
[7]Purdon, SEJones, BStip, ELabelle, AAddington, DDavid, SRet al.Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Canadian Collaborative Group for Research on cognition in schizophrenia. Arch. Gen. Psychiatry 2000;57:249258.
[8]Khan, AKhan, SRWalens, GKolts, RGiller, ELFrequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacol 2003;28:552557.
[9]Hotopf, MChurchill, RLewis, GPragmatic randomised controlled trials in psychiatry. Br. J. Psychiat. 1999;175:217223.
[10]Frackiewicz, EJSramek, JJHerrera, JMKurtz, NMCutler, NREthnicity and antipsychotic response. Ann. Pharmacother. 1997;31:13601369.
[11]Colton, TStatistics in medicine. Boston: Little, Brown and Company; 1974.
[12]Deeks, JJAltman, DGEffect measures for meta-analysis of trials with binary outcomes. In: Egger, MDavey Smith, GAltman, DG, editors. Systematic reviews in health care: meta-analysis in context (. London: BMJ Publication Group; 2001.
[13]Higgins, JPTThompson, SGDeeks, JJAltman, DGMeasuring inconsistency in meta-analysis. BMJ 2003;327:557560.
[14]Buchanan, RWBreier, AKirkpatrick, BBall, PCarpenter, WTPositive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiat. 1998;155:751760.
[15]Kane, JMMarder, SRSchooler, NRWirshing, WCUmbricht, DBaker, RWet al.Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch. Gen. Psychiatry 2001;58:965972.
[16]Rosenheck, RCramer, JXu, WThomas, JHenderson, WFrisman, Let al.A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N. Engl. J. Med. 1997;337:809815.
[17]Guirguis, EVoineskos, GGray, JSchierman, EClozapine (Leponex) vs. Chlorpromaxine (Largactil) in acute schizophrenia (a double-blind controlled study). Curr. Ther. Res. 1977;21:707719.
[18]Kane, JHonigfeld, GSinger, JMeltzer, HClozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988;45:789796.
[19]León, CATherapeutic effect of clozapine. A 4-year follow up of a controlled clinical trial. Acta Psychiatr. Scand. 1979;59:471480.
[20]Arvanitis, LAMiller, BGSeroquel Trial 13 Study Group. Multiple fixed doses of ‘Seroquel’ (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol. Psychiat. 1997;42:233246.
[21]Copolov, DLLink, CGGKowalcyk, BA multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636 ‘Seroquel’) and haloperidol in schizophrenia. Psychol. Med. 2000;30:95105.
[22]Emsley, RARaniwalla, JBailey, PJJones, AMA comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenia patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int. Clin. Psychopharm. 2000;15:121131.
[23]Peuskens, JLink, CGGA comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr. Scand. 1997;96:265273.
[24]Beasley, CMTollefson, GTran, PSatterlee, WSanger, THamilton, SOlanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol 1996;14:11123.
[25]Beasley, CM Jr.Hamilton, SHCrawford, AMDellva, Ma.Tollefson, GDTran, PVet al.Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychopharm. 1997;7:125137.
[26]Hamilton, SHEdgell, ETRevicki, DABreier, AFunctional outcome in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int. Clin. Psychopharm. 2000;15:245255.
[27]Lieberman, JATollefson, GTohen, MGreen, AIGur, REKahn, Ret al.Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiat. 2003;160:13961404.
[28]Tollefson, GDBeasley, CM Jr.Tran, PVStreet, Js.Krueger, JATamura, RNet al.Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiat. 1997;154:457465.
[29]Conley, RRTamminga, CABartko, JJRichardson, CPeszke, MLingle, Jet al.Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiat. 1998;155:914920.
[30]Ceskova, ESvestka, JDouble-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993;26:121124.
[31]Claus, ABollen, JDe Cuyper, HEneman, MMalfroid, MPeuskens, Jet al.Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr. Scand. 1992;85:295305.
[32]Csernansky, JGMahmoud, RBrenner, RA comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 2002;346:1622.
[33]Emsley, RARisperidone Working Group. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr. Bull. 1999;25:721729.
[34]Heck, AHHaffmans, PMGroot, IWHoencamp, ERisperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr. Res. 2000;46:97105.
[35]Marder, SRMeibach, RCRisperidone in the treatment of schizophrenia. Am. J. Psychiat. 1994;151:825835.
[36]Peuskens, JRisperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Brit. J. Psychiat. 1995;166:712726.
[37]Wirshing, DAMarshall, BD Jr.Green, MFMintz, JMarder, SRWirshing, WCRisperidone in treatment-refractory schizophrenia. Am. J. Psychiat. 1999;156:13741379.
[38]Volavka, JCzobor, PSheitman, BLindenmayer, JPCitrome, LMcEvoy, JPet al.Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiat. 2002;159:255262.
[39]American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed) (DSM-IV). Washington: DC: APA; 1994.
[40]Moher, DSchulz, KFAltman, DGThe CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:11911194.
[41]Review Manager (RevMan) [Computer program]. Version 4.2 for Windows. Oxford, England: The Cochrane Collaboration, 2003.
[42]Borenstein, M.Rothstein, H. Comprehensive Meta-AnalysisTM. Biostat®; 1999. http://www.MetaAnalysis.com.
[43]Leucht, SBarnes, TRKissling, WEngel, RRCorrell, CKane, JMRelapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiat. 2003;160:12091222.
[44]Leucht, SWahlbeck, KHamann, JKissling, WNew generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:15811589.
[45]Gilbory, SMBagnall, AMDuggan, LTuunainen, ARisperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review). The Cochrane library, issue 1 Chichester, UK: John Wiley & Sons, Ltd; 2004.
[46]Duggan, LFenton, MDardennes, RMEl-Dosoky, AIndran, SOlanzapine for schizophrenia (Cochrane Review). The Cochrane library, issue 1 Chichester, UK: John Wiley & Sons, Ltd; 2004.
[47]Srisurapanont, MDisayavanish, CTaimkaew, KQuetiapine for schizophrenia (Cochrane Review). The Cochrane library, issue 1 Chichester, UK: John Wiley & Sons, Ltd; 2004.
[48]Lieberman, J.McEvoy, J.Stroup, S. Clinical antipsychotic trials in intervention effectiveness (CATIE). Comparative effectiveness of antipsychotic medications in patients with schizophrenia. http://www.catie.unc.edu/schizophrenia/synopsis.html.
[49]Davis, JMChen, NGlick, IDA meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 2003;60:553564.
[50]Geddes, JFreemantle, NHarrison, PBebbington, PAtypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:13711376.
[51]Martin, JLRPérez, VSacristán, MAlvarez, EIs grey literature essential for a better control of publication bias in psychiatry? An example from three meta-analysis of schizophrenia. Eur. Psychiatry 2005 (In press).
[52]Rummel, CHamann, JKissling, Leucht, SNew generation antipsychotics for first episode schizophrenia (Cochrane Review). The Cochrane library, issue 1 Chichester, UK: John Wiley & Sons, Ltd; 2004.
[53]Gilbody, SWahlbeck, KAdams, CRandomized controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatr. Scand. 2002;105:243251.

Keywords

Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia: Submitted to European Psychiatry. A poster of this work was presented at the WPA International Congress in Florence (November 10–13, 2004). Poster session PO1: Psychotic Disorders

  • José Luis R. Martin (a1) (a2), Víctor Pérez (a3), Montse Sacristán (a1), Fernando Rodríguez-Artalejo (a4), Cristóbal Martínez (a5) and Enric Álvarez (a3)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia: Submitted to European Psychiatry. A poster of this work was presented at the WPA International Congress in Florence (November 10–13, 2004). Poster session PO1: Psychotic Disorders

  • José Luis R. Martin (a1) (a2), Víctor Pérez (a3), Montse Sacristán (a1), Fernando Rodríguez-Artalejo (a4), Cristóbal Martínez (a5) and Enric Álvarez (a3)...
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *